Background: Chronic, excessive alcohol consumption causes neurodegeneration and is associated with an increased risk for Alzheimer's disease (AD) and other dementias. Moreover, there has been a consistent rise in alcohol consumption in older adults in the past few decades. However, there is minimal research showing how alcohol consumption affects AD neuropathogenesis and biological mechanisms remain unclear. We hypothesize that mid-life chronic binge alcohol consumption accelerates AD neuropathology in the hippocampus, among the first brain regions affected by AD, through dysregulation of processes associated with AD pathogenesis.

Methods: Female triple transgenic (3xTg; n = 15) mice and non-transgenic (NonTg) control mice (B6.129; n = 13) were given EtOH binges twice/week (4g/kg) by oral gavage for 3.5 months (from 6-9.5 months) while untreated controls (3xTg n = 6 and NonTg n = 4) received sham gavages. Memory was evaluated with the novel object recognition test (NORT). RNA was extracted from the mid-brain region of one hemisphere for RNA-Sequencing (Illumina NextSeq2000; STAR/HTSeq/DESeq2 pipeline) and qPCR, while protein lysates from the opposite hemisphere's midbrain region was used for Western blot (WB) analyses. Plasma neurofilament light chain (NfL) was measured with a MesoScale Discovery kit.

Results: One week after the final EtOH gavage, hippocampal-dependent memory was significantly impaired in EtOH binged 3xTg mice, while NonTg mice were unaffected. Similarly, EtOH binge slightly increased plasma NfL in 3xTg mice, indicating persistent EtOH-induced neurodegeneration, while nonTg mice showed a significant decrease. RNA-seq from the mid-brain region containing the hippocampus revealed that chronic EtOH binge significantly affected 8477 genes (4473 up- and 4004 down-regulated) in 3xTg mice, while only 4 genes were significantly affected (2 up- and 2 down-regulated) in nonTg mice. Enrichment analyses showed EtOH altered several processes associated with neurodegeneration in 3xTg mice including regulation of synaptic plasticity and autophagy.

Conclusions: Results indicate that 3xTg mice are more sensitive to EtOH-mediated effects on neurodegeneration and memory impairment than nonTg controls. There was also significant EtOH-induced dysregulation of AD-related processes in the mid-brain of 3xTg mice, a region affected early by AD neuropathology. Together, these data show that chronic mid-life EtOH binging accelerates early AD neuropathology in 3xTg mice.

Download full-text PDF

Source
http://dx.doi.org/10.1002/alz.092570DOI Listing

Publication Analysis

Top Keywords

3xtg mice
32
alcohol consumption
16
mice
12
nontg mice
12
3xtg
9
processes associated
8
mid-brain region
8
etoh binge
8
early neuropathology
8
etoh
7

Similar Publications

Basic Science and Pathogenesis.

Alzheimers Dement

December 2024

Laboratory of Neuroscience (LIM27), Departamento e Instituto de Psiquiatria, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo, São Paulo, Brazil.

Background: Nearly all individuals with Alzheimer's disease (AD) develop neuropsychiatric symptoms (NPS). Lithium is a mood-stabilizer and is efficient in reducing disruptive behaviors in bipolar-disorder; this characteristic could be an opportunity to investigate the use of lithium in treating behavioral changes in AD.

Method: We tested lithium carbonate treatment in 3xTg-AD and age-matched Wild-type male mice (CEUA/PROCESS: 1605/2020; 4127240122).

View Article and Find Full Text PDF

Background: Exposures to hazardous noise causes irreversible injury to the structures of the inner ear, leading to changes in hearing and balance function with strong links to age-related cognitive impairment. While the role of noise-induced hearing loss in long-term health consequences, such as progression or development of Alzheimer's Disease (AD) has been suggested, the underlying mechanisms and behavioral and cognitive outcomes or therapeutic solutions to mitigate these changes remain understudied. This study aimed to characterize the association between blast exposure, hearing loss, and the progression of AD pathology, and determine the underlying mechanisms.

View Article and Find Full Text PDF

Background: Rodent models have been proved pivotal in Alzheimer's disease (AD) research. Nevertheless, the use of models that only recapitulate one aspect of AD neuropathology, and of early time points that might be excluding important features such as age-dependent inflammation and senescence, could hinder the development of effective AD therapeutics. Several tau immunotherapies are currently undergoing clinical trial.

View Article and Find Full Text PDF

Background: Late-onset Alzheimer's disease (LOAD) represents the majority of human AD cases, yet the availability of animal models that accurately reflect LOAD progression and pathology is limited. Traditional transgenic mouse models including 3xTg-AD and 5xFAD rely on supraphysiological overexpression of familial AD risk genes, failing to adequately replicate the disease progression observed in LOAD. Here, we present the first characterization of MODEL-AD1 (MAD1), a platform mouse developed by the Model Organism Development and Evaluation for Late-onset Alzheimer's Disease (MODEL-AD) Consortium.

View Article and Find Full Text PDF

Background: Ambroxol is an expectorant under study as a treatment for synucleinopathies, such as Parkinson's disease. It is a pharmacological chaperone of the lysosomal enzyme β-glucocerebrosidase (GCase), increasing this enzyme and subsequently reducing accumulation of alpha-synuclein. Although the mechanism of enhanced clearance is not fully understood, ambroxol stimulates lysosomal function through activation of transcription factor EB (TFEB), which drives hundreds of lysosomal genes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!